These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 24664619)
1. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Craddy P; Palin HJ; Johnson KI Diabetes Ther; 2014 Jun; 5(1):1-41. PubMed ID: 24664619 [TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Kay S; Strickson A; Puelles J; Selby R; Benson E; Tolley K Diabetes Ther; 2017 Apr; 8(2):251-273. PubMed ID: 28275958 [TBL] [Abstract][Full Text] [Related]
4. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062 [TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Hemmingsen B; Sonne DP; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Wu D; Li L; Liu C Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146 [TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919 [TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223 [TBL] [Abstract][Full Text] [Related]
9. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis. Wang B; Sun Y; Sang Y; Liu X; Liang J Medicine (Baltimore); 2018 Nov; 97(46):e12633. PubMed ID: 30431561 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. Baldwin D; Woods R; Lawson R; Taylor D BMJ; 2011 Mar; 342():d1199. PubMed ID: 21398351 [TBL] [Abstract][Full Text] [Related]
11. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668 [TBL] [Abstract][Full Text] [Related]
12. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525 [TBL] [Abstract][Full Text] [Related]
13. Community-based care for the management of type 2 diabetes: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(23):1-40. PubMed ID: 23074528 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Foroutan N; Muratov S; Levine M Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861 [TBL] [Abstract][Full Text] [Related]
16. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. Esposito K; Chiodini P; Maiorino MI; Capuano A; Cozzolino D; Petrizzo M; Bellastella G; Giugliano D BMJ Open; 2015 Feb; 5(2):e005892. PubMed ID: 25687897 [TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. Lin WQ; Cai ZJ; Chen T; Liu MB; Li N; Zheng B Front Endocrinol (Lausanne); 2021; 12():684960. PubMed ID: 34484112 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. Palmer SC; Mavridis D; Nicolucci A; Johnson DW; Tonelli M; Craig JC; Maggo J; Gray V; De Berardis G; Ruospo M; Natale P; Saglimbene V; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque L; Lloyd A; Ahmad N; Liu Y; Tiv S; Wiebe N; Strippoli GF JAMA; 2016 Jul; 316(3):313-24. PubMed ID: 27434443 [TBL] [Abstract][Full Text] [Related]
19. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259 [TBL] [Abstract][Full Text] [Related]